EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A SONAR report on Nirmatrelvir/ritonavir-associated rebound COVID-19: Using new databases for evaluating new diseases

Charles L Bennett iD, Joseph Magagnoli, Krishna Gundabolu, Peter Georgantopoulos iD, Akida Lebby, Gretchen Watson, Kevin Knopf, Linda Martin, Kenneth R Carson, William J Hrushesky, Chadi Nabhan, Edward Zyszkowski und 3 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0308205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Charles L Bennett und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America. Hauptthemen laut MEDLINE: Ritonavir, COVID-19 Drug Treatment, COVID-19, Social Media. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Beckman Research Institute and the City of Hope Comprehensive Cancer Center, Duarte, California.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In May 2022, the Centers for Disease Control and Prevention disseminated an alert advising that “a few” persons with Nirmatrelvir/ritonavir (NM/R)-associated rebound of COVID-19 infection had been identified. Three case reports appearing as pre-print postings described the first cases. Analyses in March 2023 by NM/R’s manufacturer and the Food and Drug Administration (FDA) reported no association between NM/R and COVID-19 rebound in a large phase 3 randomized clinical trial. Our study evaluated if social media databases or electronically disseminated new articles might provide insights related to the putative new toxicity, NM/R-associated COVID-19 rebound.

Methods

Information on NM/R-associated COVID-19 rebound cases was abstracted from preprint postings of non-peer-reviewed manuscripts, social media websites, electronically disseminated print and television media reports, a new FDA adverse event database for drugs that received Emergency Use Approval, and news articles in scientific journals.

Results

Thirty-five persons experienced presumed or documented NM/R-associated COVID-19 rebound, based on information described in preprint services (n = 27), Twitter postings and related news articles (n = 7), and news articles without related Twitter reports (n = 1). These reports included information on dates of initial COVID-19 illness and rebound onset, COVID-19 testing, vaccine status, presentation, and outcome. A new FDA safety database identified 12,500 possible cases of this toxicity, but the quality of these data was poor. Preprint postings preceded peer-reviewed publications describing the same cases by four months. Social media websites including Instagram, Reddit, YouTube, the Center for Disease Control and Prevention’s (CDC) Health Alert Network, CDC Twitter, and Facebook did not provide clinically meaningful information on individual cases.

Conclusion

Preprint services and Twitter facilitated identification of the largest case series of NM/R-associated COVID-19 rebound. The cases were reported in non-peer-reviewed media several weeks prior to the first peer-reviewed electronically disseminated publication of one person with this diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirCOVID-19 Drug TreatmentCOVID-19Social MediaHumansSARS-CoV-2Databases, FactualUnited StatesAntiviral AgentsIndazolesUnited States Food and Drug Administration

Substanzen

RitonavirAntiviral AgentsIndazoles

Autor:innen und Institutionen

  • Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.
  • Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, United States of America.
  • Division of Hematology/Oncology, Department of Internal Medicine, Omaha School of Medicine University of Nebraska, Omaha, Nebraska, United States of America.
  • Hematology/Oncology, Highland Hospital, Alameda Health System, Oakland, California, United States of America.
  • Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine Northwestern University, Chicago, Illinois, United States of America.
  • Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.

ORCID-Profile: Charles L Bennett, Peter Georgantopoulos

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Beckman Research Institute and the City of Hope Comprehensive Cancer Center, Duarte, California

Zitieren

APA

Bennett, C. L., Magagnoli, J., Gundabolu, K., Georgantopoulos, P., Lebby, A., Watson, G., Knopf, K., Martin, L., Carson, K. R., Hrushesky, W. J., Nabhan, C., Zyszkowski, E., Smith, E. B., Gale, R. P., & Rosen, S. T. (2024). A SONAR report on Nirmatrelvir/ritonavir-associated rebound COVID-19: Using new databases for evaluating new diseases. PLOS ONE. https://doi.org/10.1371/journal.pone.0308205

Vancouver

Bennett CL, Magagnoli J, Gundabolu K, Georgantopoulos P, Lebby A, Watson G, et al. A SONAR report on Nirmatrelvir/ritonavir-associated rebound COVID-19: Using new databases for evaluating new diseases. PLOS ONE. 2024. doi:10.1371/journal.pone.0308205

BibTeX
@article{Bennett2024,
  author = {Bennett, Charles L and Magagnoli, Joseph and Gundabolu, Krishna and Georgantopoulos, Peter and Lebby, Akida and Watson, Gretchen and Knopf, Kevin and Martin, Linda and Carson, Kenneth R and Hrushesky, William J and Nabhan, Chadi and Zyszkowski, Edward and Smith, Edward B and Gale, Robert Peter and Rosen, Steven T},
  title = {A SONAR report on Nirmatrelvir/ritonavir-associated rebound COVID-19: Using new databases for evaluating new diseases},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0308205}
}
Kostenlos starten →